1. Home /
  2. Biotechnology

Biotechnology

RA Pharmaceuticals Soars on Deal to Be Acquired for $2.1 Billion

RA Pharmaceuticals Soars on Deal to Be Acquired for $2.1 Billion

Shares of biotech company Ra Pharmaceuticals more than double after Belgian-based biotech firm UCB announces it is acquiring the company for $2.1 billion in cash.

I'm Unapologetically Overweight in These 2 Sectors

I'm Unapologetically Overweight in These 2 Sectors

The two are homebuilding and biotech, and there are stocks within those sectors where I've parked my money.

Nektar Shares Drop After Double Downgrade to Sell at Goldman Sachs

Nektar Shares Drop After Double Downgrade to Sell at Goldman Sachs

Goldman also slashes its one-year price target by nearly two-thirds on expectations that Nektar's in-the-works cancer treatment won't generate revenue anytime soon.

Qiagen Tumbles on Sales Warning, CEO Departure

Qiagen Tumbles on Sales Warning, CEO Departure

Shares of Qiagen slide after the company warns its third-quarter sales will be lower than expected and that its CEO is resigning.

Sage Therapeutics Is Pointed Down So We Are In No Rush to Buy

Sage Therapeutics Is Pointed Down So We Are In No Rush to Buy

Let's check and see if the charts and indicators suggest where prices might bottom out.

Lantheus and Progenics Sink After Striking All-Stock Deal

Lantheus and Progenics Sink After Striking All-Stock Deal

Lantheus will acquire oncology medicine developer Progenics Pharmaceuticals in an all-stock deal.

Placid Indices Cover Up an Extremely Difficult Trading Market

Placid Indices Cover Up an Extremely Difficult Trading Market

The technical pattern of the indices actually looks quite promising, but under the surface is a different story.

Market Wrap: Cigna Is Well Positioned Despite Political Headwinds

Market Wrap: Cigna Is Well Positioned Despite Political Headwinds

Cigna shares rose after being upgraded to outperform by analysts at BMO Capital.

Seattle Genetics Climbs on Positive Trial Results for Bladder Cancer Treatment

Seattle Genetics Climbs on Positive Trial Results for Bladder Cancer Treatment

Analysts at Stifel raise their price target on the stock to $95.

Immunomedics Stock Drops After Bladder-Cancer-Drug Results Disappoint

Immunomedics Stock Drops After Bladder-Cancer-Drug Results Disappoint

The company's treatment candidate showed a lower response rate than a competitor's.